Healthcare

Alterity Therapeutics (ASX:ATH) has strengthened its near-term funding position after an underwriting arrangement converted an expiring options shortfall into A$4.2 million of gross proceeds.

LTR Pharma (ASX:LTP) is broadening its commercial strategy beyond erectile dysfunction through a new Australian pilot agreement covering KYZATREX, an oral testosterone undecanoate capsule developed by US-based Marius Pharmaceuticals.

• Echo IQ is progressing regulatory work for its cardiac decision-support technology in the United States.

A repeat order from a major global pharmaceutical company is an important commercial development for an emerging ASX technology business. On 7 September 2026, Adelaide-based Clever Culture Systems (ASX:CC5) announced that Novo Nordisk had ordered two additional APAS Independence instruments, lifting its installed base …

• The United States approval covers distal cholangiocarcinoma under a humanitarian device exemption.

• The certification is a prerequisite for adding Cyclotek as a critical subcontractor to OncoSil Medical's Notified Body (NB) certificate.

Sonic Healthcare Limited (ASX:SHL) shares were trading marginally lower on Wednesday, with the stock at A$19.52, down 0.15% at the time of writing on 9 September 2026.